Edaravone Dexborneol Versus Edaravone Alone for the Treatment of Acute Ischemic Stroke

依达拉奉 医学 改良兰金量表 随机化 麻醉 内科学 随机对照试验 临床试验 缺血性中风 缺血
作者
Jie Xu,Anxin Wang,Xia Meng,Gulbahram Yalkun,Chunxue Wang,Zhiqiang Gao,Dawei Chen,Yong Ji,Jun Xu,Deqin Geng,Runxiu Zhu,Bo Liu,Aiqin Dong,Hua Mu,Zhihong Lu,Shuya Li,Huaguang Zheng,Xia Chen,Yilong Wang,Xingquan Zhao
出处
期刊:Stroke [Lippincott Williams & Wilkins]
卷期号:52 (3): 772-780 被引量:153
标识
DOI:10.1161/strokeaha.120.031197
摘要

Background and Purpose: Edaravone dexborneol, comprised of 2 active ingredients, edaravone and (+)-borneol, has been developed as a novel neuroprotective agent with synergistic effects of antioxidant and anti-inflammatory in animal models. The present clinical trial aimed at testing the effects of edaravone dexborneol versus edaravone on 90-day functional outcome in patients with acute ischemic stroke (AIS). Methods: A multicenter, randomized, double-blind, comparative, phase III clinical trial was conducted at 48 hospitals in China between May 2015 and December 2016. Inclusion criteria included patients diagnosed as AIS, 35 to 80 years of age, National Institutes of Health Stroke Scale Score between 4 and 24, and within 48 hours of AIS onset. AIS patients were randomized in 1:1 ratio into 2 treatment arms: 14-day infusion of edaravone dexborneol or edaravone injection. The primary end point was the proportion of patients with modified Rankin Scale score ≤1 on day 90 after randomization. Results: One thousand one hundred sixty-five AIS patients were randomly allocated to the edaravone dexborneol group (n=585) or the edaravone group (n=580). The edaravone dexborneol group showed significantly higher proportion of patients experiencing good functional outcomes on day 90 after randomization, compared with the edaravone group (modified Rankin Scale score ≤1, 67.18% versus 58.97%; odds ratio, 1.42 [95% CI, 1.12–1.81]; P =0.004). The prespecified subgroup analyses indicated that a greater benefit was observed in female patients than their male counterparts (2.26, 1.49–3.43 versus 1.14, 0.85–1.52). Conclusions: When edaravone dexborneol versus edaravone was administered within 48 hours after AIS, 90-day good functional outcomes favored the edaravone dexborneol group, especially in female patients. Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT02430350.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
若水完成签到 ,获得积分10
刚刚
SYLH应助tian采纳,获得10
刚刚
脑洞疼应助tian采纳,获得10
1秒前
Ava应助tian采纳,获得10
1秒前
领导范儿应助tian采纳,获得10
1秒前
桐桐应助tian采纳,获得10
1秒前
乐乐应助tian采纳,获得10
1秒前
乐乐应助tian采纳,获得10
1秒前
wbscz应助tian采纳,获得10
1秒前
ding应助tian采纳,获得10
1秒前
1秒前
研友_LBRPOL完成签到,获得积分10
3秒前
gao完成签到 ,获得积分10
4秒前
zq发布了新的文献求助10
4秒前
韭黄发布了新的文献求助10
5秒前
她的城完成签到,获得积分0
5秒前
单薄的钢笔完成签到,获得积分10
7秒前
568923完成签到,获得积分10
9秒前
Grace159完成签到 ,获得积分10
12秒前
咖啡博士发布了新的文献求助10
14秒前
彦祖i学术完成签到,获得积分10
16秒前
zq完成签到,获得积分20
17秒前
HY完成签到,获得积分10
18秒前
不再挨训完成签到 ,获得积分10
19秒前
学术乞丐完成签到,获得积分20
21秒前
咖啡博士完成签到,获得积分10
22秒前
韭黄发布了新的文献求助10
23秒前
Singularity完成签到,获得积分0
25秒前
JamesPei应助zq采纳,获得10
26秒前
所所应助韭黄采纳,获得10
30秒前
江霭完成签到,获得积分10
33秒前
鲤鱼青槐完成签到,获得积分10
42秒前
量子星尘发布了新的文献求助10
43秒前
46秒前
缥缈的冰旋完成签到,获得积分10
46秒前
52秒前
53秒前
ailemonmint完成签到 ,获得积分10
53秒前
54秒前
玉ER完成签到,获得积分10
55秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038112
求助须知:如何正确求助?哪些是违规求助? 3575788
关于积分的说明 11373801
捐赠科研通 3305604
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022